CBCleo Lucinda Bishop

Cleo Lucinda Bishop

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cleo Lucinda Bishop has a total of 153 co-authors. Here are the top co-authors by number of shared publications:

  • Ryan Wallis

    Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK

    10 shared publications
  • Eleanor Jane. Tyler

    Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK

    7 shared publications
  • Bethany K. Hughes

    Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK

    6 shared publications
  • Deborah Milligan

    Blizard Institute, Barts and The London Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK

    5 shared publications
  • James C. Garbe

    Life Science Division, Lawrence Berkeley National Laboratory, Berkeley, USA

    5 shared publications
  • Martha R. Stampfer

    Life Science Division, Lawrence Berkeley National Laboratory, Berkeley, USA

    5 shared publications

Latest Publications

  • Goals and challenges for senescence research

    by Cleo L. Bishop, Feyza Engin, Jing-Dong Jackie Han, Valery Krizhanovsky, Guang-Hui Liu, Ana O’LOghlen, João F. Passos, Zhongjun Zhou

  • A consensus roadmap from the SENESCENCE2030 network towards precision senescence medicine

    by Aniello Cerrato, Antonella Farsetti, Laura Bordoni, Raquel Rua Martins, Iker Bengoetxea de Tena, Ivana Vrhovac Madunic, Marziyya Mammadova, Stefano Raviola, Mohamad Rima, Minenur Ozturk, et al.

  • Open Access

    SAMP-Score: a morphology-based machine learning classification method for screening pro-senescence compounds in p16 positive cancer cells

    by Ryan Wallis, Bethany K. Hughes, Madeleine Moore, Emily A. O’sUllivan, Luke C. McIlvenna, Luke Gammon, Anthony Hope, Fiona Bellany, Parul Dixit, Claire Mackenzie, et al.

    Background: Senescence identification is rendered challenging due to a lack of universally available biomarkers. This represents a bottleneck in efforts to develop pro-senescence therapeutics – agents designed to induce the arrest of cellular proliferation associated with a senescence response in cancer cells for therapeutic gain. This is particularly true in contexts such as basal-like breast cancer (BLBC), which often express high levels of widely reported senescence hallmarks, which has led to the designation of these subtypes as senescence marker positive (Sen-Mark+). Unfortunately, these are often cancers with the most limited treatment options, where novel pro-senescence compounds would be of potential clinical utility. Results: To address these challenges, we have developed SAMP-Score, a machine learning classification tool for identifying senescence induction in Sen-Mark+ cancers. This technique builds upon our previous observation that senescent cells develop distinct senescence-associated morphological profiles (SAMPs), which can be assessed readily in traditionally challenging contexts for senescence identification, including high-throughput screens. Conclusions: Through application of SAMP-Score, we have identified QM5928, a novel pro-senescence compound, that is able to induce senescence in a variety of Sen-Mark+ cancers and has potential utility as a tool molecule to explore the mechanisms and pathways through which senescence induction occurs in these cells.


  • Open Access

    SAMP-Score: A morphology-based machine learning classification method for screening pro-senescence compounds in p16 positive cancer cells

    by Ryan Wallis, Bethany K. Hughes, Madeleine Moore, Emily A. O’SUllivan, Luke C. McIlvenna, Luke Gammon, Anthony Hope, Fiona Bellany, Claire Mackenzie, Charlotte Green, et al.

    Background Senescence identification is rendered challenging due to a lack of universally available biomarkers. This represents a bottleneck in efforts to develop pro-senescence therapeutics – agents designed to induce the arrest of cellular proliferation associated with a senescence response in cancer cells for therapeutic gain. This is particularly true in contexts such as basal-like breast cancer (BLBC), which often express high levels of widely reported senescence hallmarks, which has led to the designation of these subtypes as senescence marker positive (Sen-Mark+). Unfortunately, these are often cancers with the most limited treatment options, where novel pro-senescence compounds would be of potential clinical utility. Results To address these challenges, we have developed SAMP-Score, a machine learning classification tool for identifying senescence induction in Sen-Mark+ cancers. This technique builds upon our previous observation that senescent cells develop distinct senescence-associated morphological profiles (SAMPs), which can be assessed readily in traditionally challenging contexts for senescence identification, including high-throughput screens. Conclusions Through application of SAMP-Score, we have identified QM5928, a novel pro-senescence compound, that is able to induce senescence in a variety of Sen-Mark+ cancers and has potential utility as a tool molecule to explore the mechanisms and pathways through which senescence induction occurs in these cells.

  • Open Access

    SenPred: a single-cell RNA sequencing-based machine learning pipeline to classify deeply senescent dermal fibroblast cells for the detection of an in vivo senescent cell burden

    by Bethany K. Hughes, Andrew Davis, Deborah Milligan, Ryan Wallis, Federica Mossa, Michael P. Philpott, Linda J. Wainwright, David A. Gunn, Cleo L. Bishop

    Background: Senescence classification is an acknowledged challenge within the field, as markers are cell-type and context dependent. Currently, multiple morphological and immunofluorescence markers are required. However, emerging scRNA-seq datasets have enabled an increased understanding of senescent cell heterogeneity. Methods: Here we present SenPred, a machine-learning pipeline which identifies fibroblast senescence based on single-cell transcriptomics from fibroblasts grown in 2D and 3D. Results: Using scRNA-seq of both 2D and 3D deeply senescent fibroblasts, the model predicts intra-experimental fibroblast senescence to a high degree of accuracy (> 99% true positives). Applying SenPred to in vivo whole skin scRNA-seq datasets reveals that cells grown in 2D cannot accurately detect fibroblast senescence in vivo. Importantly, utilising scRNA-seq from 3D deeply senescent fibroblasts refines our ML model leading to improved detection of senescent cells in vivo. This is context specific, with the SenPred pipeline proving effective when detecting senescent human dermal fibroblasts in vivo, but not the senescence of lung fibroblasts or whole skin. Conclusions: We position this as a proof-of-concept study based on currently available scRNA-seq datasets, with the intention to build a holistic model to detect multiple senescent triggers using future emerging datasets. The development of SenPred has allowed for the detection of an in vivo senescent fibroblast burden in human skin, which could have broader implications for the treatment of age-related morbidities. All code for the SenPred pipeline is available at the following URL: https://github.com/bethk-h/SenPred_HDF.


  • Open Access

    The paradox of senescent-marker positive cancer cells: challenges and opportunities

    by Emily A. O’sUllivan, Ryan Wallis, Federica Mossa, Cleo L. Bishop

    Senescence is an anti-tumour mechanism and hallmark of cancer. Loss or mutation of key senescence effectors, such as p16INK4A, are frequently observed in cancer. Intriguingly, some human tumours are both proliferative and senescent-marker positive (Sen-Mark+). Here, we explore this paradox, focusing on the prognostic consequences and the current challenges in classifying these cells. We discuss future strategies for Sen-Mark+ cell detection together with emerging opportunities to exploit senescence for cancer.


  • The promise of machine learning approaches to capture cellular senescence heterogeneity

    by Imanol Duran, Cleo L. Bishop, Jesús Gil, Ryan Wallis


  • Open Access

    An expedited screening platform for the discovery of anti-ageing compounds in vitro and in vivo

    by Celia Lujan, Eleanor Jane Tyler, Simone Ecker, Amy Philomena Webster, Eleanor Rachel Stead, Victoria Eugenia Martinez-Miguel, Deborah Milligan, James Charles Garbe, Martha Ruskin Stampfer, Stephan Beck, et al.

    Background: Restraining or slowing ageing hallmarks at the cellular level have been proposed as a route to increased organismal lifespan and healthspan. Consequently, there is great interest in anti-ageing drug discovery. However, this currently requires laborious and lengthy longevity analysis. Here, we present a novel screening readout for the expedited discovery of compounds that restrain ageing of cell populations in vitro and enable extension of in vivo lifespan. Methods: Using Illumina methylation arrays, we monitored DNA methylation changes accompanying long-term passaging of adult primary human cells in culture. This enabled us to develop, test, and validate the CellPopAge Clock, an epigenetic clock with underlying algorithm, unique among existing epigenetic clocks for its design to detect anti-ageing compounds in vitro. Additionally, we measured markers of senescence and performed longevity experiments in vivo in Drosophila, to further validate our approach to discover novel anti-ageing compounds. Finally, we bench mark our epigenetic clock with other available epigenetic clocks to consolidate its usefulness and specialisation for primary cells in culture. Results: We developed a novel epigenetic clock, the CellPopAge Clock, to accurately monitor the age of a population of adult human primary cells. We find that the CellPopAge Clock can detect decelerated passage-based ageing of human primary cells treated with rapamycin or trametinib, well-established longevity drugs. We then utilise the CellPopAge Clock as a screening tool for the identification of compounds which decelerate ageing of cell populations, uncovering novel anti-ageing drugs, torin2 and dactolisib (BEZ-235). We demonstrate that delayed epigenetic ageing in human primary cells treated with anti-ageing compounds is accompanied by a reduction in senescence and ageing biomarkers. Finally, we extend our screening platform in vivo by taking advantage of a specially formulated holidic medium for increased drug bioavailability in Drosophila. We show that the novel anti-ageing drugs, torin2 and dactolisib (BEZ-235), increase longevity in vivo. Conclusions: Our method expands the scope of CpG methylation profiling to accurately and rapidly detecting anti-ageing potential of drugs using human cells in vitro, and in vivo, providing a novel accelerated discovery platform to test sought after anti-ageing compounds and geroprotectors.


  • Open Access

    Author Correction: The senescent methylome and its relationship with cancer, ageing and germline genetic variation in humans

    by Robert Lowe, Marita G. Overhoff, Sreeram V. Ramagopalan, James C. Garbe, James Koh, Martha R. Stampfer, David H. Beach, Vardhman K. Rakyan, Cleo L. Bishop